PD‑1‑Positive Cells Contribute to the Diagnosis of Inflammatory Bowel Disease and Can Aid in Predicting Response to Vedolizumab

Kim et al., 2023

Anti–PD-1 Antibodies Recognizing the Membrane Proximal Region are PD-1 Agonists that can Downregulate Inflammatory Diseases

Suzuki et al., 2023

PD-1 and PD-1 Ligands: From Discovery to Clinical Application

Okazaki et al., 2020

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial

Warren et al., 2023

Immune Checkpoint Inhibitor PD-1 Pathway is Down-Regulated in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression

Guo et al., 2018

Coupling Mammalian Cell Surface Display With Somatic Hypermutation for the Discovery and Maturation of Human Antibodies

Bowers et al., 2011

Mammalian Cell Display for the Discovery and Optimization of Antibody Therapeutics

Bowers et al., 2014

Humanization of Antibodies Using Heavy Chain Complementarity-Determining Region 3 Grafting Coupled with in Vitro Somatic Hypermutation

Bowers et al., 2013

High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and In Vitro Somatic Hypermutation

McConnell et al., 2012

Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD-1 Antibody with Potent Activity to Enhance Immune Function in in Vitro Cellular Assays and in Vivo Animal Models

Kumar et al., 2021

The Majority of Generalized Pustular Psoriasis Without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist

Sugiura et al., 2013

IL-36 in Psoriasis

Towne et al., 2012

IL-36: a Potential Psoriasis Target?

Raison et al., 2012

The Biochemistry of Somatic Hypermutation

Peled et al., 2005